IL105078A - Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type - Google Patents

Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type

Info

Publication number: IL105078A
Authority: IL; Israel
Prior art keywords: carbon atoms; pyridyl; beta; hydrogen atom; alkyl
Prior art date: 1992-03-31

Application number

IL105078A

Other languages

English (en)

Other versions

IL105078A0 (en

Original Assignee

British Tech Group

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-31

Filing date

1993-03-16

Publication date

1997-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL105078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-31 Priority claimed from GB929207057A external-priority patent/GB9207057D0/en

1992-11-27 Priority claimed from GB929224880A external-priority patent/GB9224880D0/en

1993-03-16 Application filed by British Tech Group filed Critical British Tech Group

1993-07-08 Publication of IL105078A0 publication Critical patent/IL105078A0/xx

1997-11-20 Publication of IL105078A publication Critical patent/IL105078A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL105078A 1992-03-31 1993-03-16 Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type IL105078A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929207057A GB9207057D0 (en)	1992-03-31	1992-03-31	Steroids
GB929224880A GB9224880D0 (en)	1992-11-27	1992-11-27	Steroids

Publications (2)

Publication Number	Publication Date
IL105078A0 IL105078A0 (en)	1993-07-08
IL105078A true IL105078A (en)	1997-11-20

Family

ID=26300621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL105078A IL105078A (en)	1992-03-31	1993-03-16	Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type

Country Status (16)

Country	Link
EP (1)	EP0633893B1 (xx)
JP (1)	JP2742331B2 (xx)
KR (1)	KR100235135B1 (xx)
AT (1)	ATE186913T1 (xx)
AU (1)	AU668144B2 (xx)
CA (1)	CA2132449C (xx)
CZ (1)	CZ287434B6 (xx)
DE (2)	DE69327096T2 (xx)
DK (1)	DK0633893T3 (xx)
ES (1)	ES2138618T3 (xx)
GB (1)	GB2265624B (xx)
IL (1)	IL105078A (xx)
LU (1)	LU91911I2 (xx)
MX (1)	MX9301525A (xx)
NZ (1)	NZ249911A (xx)
WO (1)	WO1993020097A1 (xx)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69416419T2 (de) *	1993-09-30	1999-06-10	Btg International Ltd., London	Synthese von 17-(3-pyridyl) steroiden
DK0724591T3 (da) *	1993-10-27	1999-09-27	Merrell Pharma Inc	Delta 16 umættede C17-heterocycliske steroider anvendelige som steroid C17-20 lyaseinhibitorer
CN1329394C (zh)	2000-11-17	2007-08-01	武田药品工业株式会社	新咪唑衍生物、其制备方法及其用途
ATE502030T1 (de)	2000-11-20	2011-04-15	Takeda Pharmaceutical	Imidazolderivate, verfahren zu deren herstellung und deren verwendung
AU2002221080A1 (en)	2000-12-08	2002-06-18	Masami Kusaka	Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
CA2470214A1 (en) *	2001-12-13	2003-06-26	Abbott Laboratories	3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US20040138187A1 (en) *	2002-08-28	2004-07-15	Reading Christopher L.	Therapeutic treatment methods
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
GB0418900D0 (en) *	2004-08-24	2004-09-29	Btg Int Ltd	Novel salt forms
JP5199667B2 (ja) *	2004-08-24	2013-05-15	ビーティージー・インターナショナル・リミテッド	中間体としての１７−ｏ−ビニル−トリフレートの調製のための方法
DE102006008074B4 (de) *	2006-02-22	2013-08-14	RUHR-UNIVERSITäT BOCHUM	Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
RS62034B1 (sr)	2006-08-25	2021-07-30	Janssen Oncology Inc	Kompozicije za lečenje raka
CA2661546A1 (en) *	2006-08-25	2008-02-28	Cougar Biotechnology, Inc.	Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2009009132A1 (en) *	2007-07-12	2009-01-15	Cougar Biotechnology, Inc.	Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US20100048914A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) *	2009-02-05	2016-05-25	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
UA105794C2 (uk)	2009-06-26	2014-06-25	Новартіс Аг	1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
WO2011059969A2 (en) *	2009-11-13	2011-05-19	Tokai Pharmaceuticals, Inc.	Mammalian metabolites of steroids
WO2011088160A2 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
KR101823275B1 (ko)	2010-08-04	2018-03-08	펠피큐어 파마슈티걸즈 아이엔씨	전립선 암종의 치료를 위한 병용 요법
JP2013537210A (ja)	2010-09-16	2013-09-30	ノバルティスアーゲー	１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CN102558274B (zh) *	2010-12-08	2014-10-15	深圳万乐药业有限公司	一种适合工业化生产醋酸阿比特龙的合成方法
CN103282358A (zh) *	2010-12-16	2013-09-04	生化马林制药公司	C-17-杂芳基类固醇化合物作为cyp11b、cyp17 及/或cyp21 抑制剂
CN102558275A (zh) *	2010-12-20	2012-07-11	天津药物研究院	α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
EA023064B1 (ru)	2011-04-28	2016-04-29	Новартис Аг	ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
CN102321142A (zh) *	2011-09-29	2012-01-18	重庆医药工业研究院有限责任公司	一种醋酸阿比特龙晶型及其制备方法
DE102011083725A1 (de) *	2011-09-29	2013-04-04	Bayer Pharma AG	Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9353145B2 (en) *	2011-10-10	2016-05-31	Zach System	Process for preparing 17-substituted steroids
CN103059090B (zh) *	2011-10-20	2016-06-22	连云港润众制药有限公司	醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
KR102035361B1 (ko)	2011-11-30	2019-11-08	아스트라제네카 아베	암의 병용 치료
CN103172690B (zh) *	2011-12-23	2016-08-24	重庆医药工业研究院有限责任公司	醋酸阿比特龙及其中间体的制备方法
EP2607371A1 (en)	2011-12-23	2013-06-26	Crystal Pharma, S.A.U.	Processes for the preparation of abiraterone and related compouds
CN105461777B (zh) *	2012-01-04	2017-07-18	连云港润众制药有限公司	一种醋酸阿比特龙的纯化方法
CN103254265B (zh)	2012-02-21	2016-07-13	上海希迈医药科技有限公司	醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) *	2012-03-23	2016-04-13	山东新时代药业有限公司	一种醋酸阿比特龙的制备方法
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
WO2013159225A1 (en) *	2012-04-23	2013-10-31	Alphora Research Inc.	Process for preparation of 17-substituted steroids
WO2013184621A1 (en)	2012-06-06	2013-12-12	Novartis Ag	Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CN102731605B (zh) *	2012-06-19	2016-04-13	鲁南制药集团股份有限公司	一种醋酸阿比特龙的纯化方法
BR112015000443A2 (pt) *	2012-07-10	2017-06-27	Bayer Pharma AG	derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
WO2014009436A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Nanosuspension of abiraterone acetate
WO2014009434A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Oxidation stability of abiraterone acetate
WO2014016830A1 (en) *	2012-07-25	2014-01-30	Mapi Pharma Ltd.	Process and intermediates for the preparation of abiraterone acetate
WO2014058785A1 (en)	2012-10-10	2014-04-17	Novartis Ag	Combination therapy
ITMI20121788A1 (it)	2012-10-22	2014-04-23	Olon Spa	Procedimento per la purificazione di abiraterone acetato
WO2014071983A1 (en)	2012-11-09	2014-05-15	Synthon Bv	Process for making the 17-triflate intermediate of abiraterone-3-acetate
CA2890589A1 (en)	2012-11-09	2014-05-15	Synthon Bv	Process for making abiraterone-3-acetate
TWI570131B (zh) *	2012-11-13	2017-02-11	賽克系統公司	製備１７－經取代類固醇之方法
WO2014075978A1 (en)	2012-11-16	2014-05-22	Synthon B.V.	Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) *	2012-11-22	2017-04-19	常州靶点医药科技有限公司	一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) *	2012-12-12	2014-06-18	天津大学	阿比特龙醋酸酯的制备方法
EP2938625B1 (en)	2012-12-31	2018-02-21	Hetero Research Foundation	Process for the preparation of abiraterone acetate
KR20150127720A (ko)	2013-03-14	2015-11-17	유니버시티 오브 매릴랜드, 발티모어	안드로겐 수용체 하향 조절제 및 그의 용도
US20160022606A1 (en)	2013-03-14	2016-01-28	Pellficure Pharmaceuticals Inc.	Novel therapy for prostate carcinoma
PL2792682T3 (pl)	2013-04-19	2017-04-28	Zach System	Sposób wytwarzania stałej postaci octanu abirateronu
EP3013844A4 (en) *	2013-06-24	2017-03-01	Sun Pharmaceutical Industries LTD	Process for preparation of abiraterone acetate
WO2015014686A1 (en)	2013-07-29	2015-02-05	Industriale Chimica S.R.L.	Process for the preparation of abiraterone or abiraterone acetate
US9650410B2 (en)	2013-07-29	2017-05-16	Industriale Chimica S.R.L.	Process for the preparation of abiraterone and abiraterone acetate
ITMI20131861A1 (it) *	2013-11-08	2015-05-09	Ind Chimica Srl	Processo per la preparazione di abiraterone e abiraterone acetato
WO2015023710A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN104558091B (zh) *	2013-10-16	2017-07-28	天津金耀集团有限公司	一种醋酸阿比特龙的合成方法
US9556219B2 (en)	2014-01-28	2017-01-31	Olon S.P.A.	Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh)	2014-04-21	2016-01-20	武汉百科药物开发有限公司	一种醋酸阿比特龙的制备方法
US9315541B2 (en)	2014-05-20	2016-04-19	Olon S.P.A.	Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
EP3160450A1 (en)	2014-06-30	2017-05-03	Galenicum Health S.L.	Stable pharmaceutical compositions in the form of immediate release tablets
CZ2014475A3 (cs)	2014-07-09	2016-01-20	Zentiva, K.S.	Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
EP3191087A1 (en)	2014-09-12	2017-07-19	Pellficure Pharmaceuticals, Inc.	Compositions and methods for treatment of prostate carcinoma
CA2969675C (en)	2014-12-05	2023-06-06	Aragon Pharmaceuticals, Inc.	Anticancer compositions
BR112017011788A2 (pt)	2014-12-05	2017-12-26	Aragon Pharmaceuticals Inc	composições anticâncer
EP3280448B1 (en)	2015-04-10	2020-12-30	Capsugel Belgium NV	Abiraterone acetate lipid formulations
CN108541255B (zh)	2016-02-02	2019-06-14	深圳市塔吉瑞生物医药有限公司	一种甾体类化合物及包含该化合物的组合物及其用途
TW201808287A (zh)	2016-06-03	2018-03-16	美商艾瑞岡醫藥公司	抗癌組成物
WO2018023017A1 (en)	2016-07-29	2018-02-01	Janssen Pharmaceutica Nv	Methods of treating prostate cancer
EP3528799A1 (en)	2016-10-24	2019-08-28	Pellficure Pharmaceuticals, Inc.	Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
US11865215B2 (en)	2018-04-26	2024-01-09	Synthon B.V.	Tablet compositions comprising abiraterone acetate
HU231297B1 (hu)	2018-07-31	2022-09-28	Richter Gedeon Nyrt	Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) *	2019-07-15	2019-09-24	成都贝诺科成生物科技有限公司	阿比特龙衍生物、其制备方法与应用
EP4009969A1 (en)	2019-08-08	2022-06-15	Laekna Limited	Method of treating cancer
EP3854384A1 (en)	2020-01-27	2021-07-28	Adamed Pharma S.A.	Pharmaceutical formulation comprising abiraterone acetate
WO2021224471A1 (en)	2020-05-08	2021-11-11	Janssen Pharmaceutica Nv	Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en)	2020-07-30	2022-02-02	Galenicum Health S.L.U.	Abiraterone for use in a method of treating cancer
WO2023148345A1 (en)	2022-02-04	2023-08-10	Janssen Pharmaceutica Nv	Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2023155846A1 (zh) *	2022-02-18	2023-08-24	上海醇健医药技术有限公司	17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物
CN116589519A (zh) *	2023-05-17	2023-08-15	江西川奇药业有限公司	一种醋酸阿比特龙及其中间产物的合成方法
WO2025027138A1 (en)	2023-08-02	2025-02-06	Janssen Pharmaceutica Nv	Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ224288A (en) *	1987-04-22	1989-12-21	Merrell Dow Pharma	17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

1993
- 1993-03-15 DE DE69327096T patent/DE69327096T2/de not_active Expired - Lifetime
- 1993-03-15 AT AT93906670T patent/ATE186913T1/de active
- 1993-03-15 GB GB9305269A patent/GB2265624B/en not_active Expired - Lifetime
- 1993-03-15 WO PCT/GB1993/000531 patent/WO1993020097A1/en not_active Ceased
- 1993-03-15 NZ NZ249911A patent/NZ249911A/en not_active IP Right Cessation
- 1993-03-15 DK DK93906670T patent/DK0633893T3/da active
- 1993-03-15 ES ES93906670T patent/ES2138618T3/es not_active Expired - Lifetime
- 1993-03-15 CA CA002132449A patent/CA2132449C/en not_active Expired - Lifetime
- 1993-03-15 EP EP93906670A patent/EP0633893B1/en not_active Expired - Lifetime
- 1993-03-15 CZ CZ19942337A patent/CZ287434B6/cs not_active IP Right Cessation
- 1993-03-15 KR KR1019940703426A patent/KR100235135B1/ko not_active Expired - Lifetime
- 1993-03-15 AU AU37584/93A patent/AU668144B2/en not_active Expired
- 1993-03-15 JP JP5517187A patent/JP2742331B2/ja not_active Expired - Lifetime
- 1993-03-16 IL IL105078A patent/IL105078A/xx active Protection Beyond IP Right Term
- 1993-03-18 MX MX9301525A patent/MX9301525A/es active IP Right Grant
2011
- 2011-12-07 LU LU91911C patent/LU91911I2/fr unknown
2012
- 2012-01-12 DE DE201212000012 patent/DE122012000012I1/de active Pending

Also Published As

Publication number	Publication date
CA2132449C (en)	2002-09-10
DE122012000012I1 (de)	2012-06-14
WO1993020097A1 (en)	1993-10-14
ATE186913T1 (de)	1999-12-15
LU91911I2 (fr)	2012-02-07
GB9305269D0 (en)	1993-05-05
KR950700923A (ko)	1995-02-20
NZ249911A (en)	1996-06-25
EP0633893B1 (en)	1999-11-24
ES2138618T3 (es)	2000-01-16
GB2265624A (en)	1993-10-06
AU3758493A (en)	1993-11-08
KR100235135B1 (ko)	2000-01-15
JPH07505377A (ja)	1995-06-15
CA2132449A1 (en)	1993-10-14
AU668144B2 (en)	1996-04-26
JP2742331B2 (ja)	1998-04-22
CZ287434B6 (en)	2000-11-15
EP0633893A1 (en)	1995-01-18
IL105078A0 (en)	1993-07-08
DK0633893T3 (da)	2000-04-17
GB2265624B (en)	1995-04-19
DE69327096D1 (de)	1999-12-30
CZ233794A3 (en)	1995-02-15
MX9301525A (es)	1994-02-28
DE69327096T2 (de)	2000-06-21

Publication	Publication Date	Title
IL105078A (en)	1997-11-20	Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type
RU2210574C2 (ru)	2003-08-20	Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
CA2467222A1 (en)	2003-05-22	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
TW240215B (xx)	1995-02-11
GEP20012530B (en)	2001-09-25	Neuroactive Steroids of the Androstane and Pregnane Series
ZA899671B (en)	1990-11-28	Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
MY114394A (en)	2002-10-31	Estra-1,3,5 (10)-trien derivatives,process for their preparation and pharmaceutical compositions containing these compounds
IL72702A0 (en)	1984-11-30	Steroidal carboxylic acid esters,their manufacture and pharmaceutical compositions containing them
ZA906710B (en)	1991-09-25	7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase
PT92168B (pt)	1995-07-03	Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleos de estrogenios para provocar a inibicao da actividade de esteroides sexuais
ZA929315B (en)	1993-05-24	17-spirofuran-3'-ylidene steroids.
ZA929859B (en)	1993-12-20	19-nor steroids having a thiocarbon chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them
JP2000509388A (ja)	2000-07-25	抗炎症薬剤として有用なステロイドナイトレートエステル誘導体を含有する新規医薬組成物
IL87894A0 (en)	1989-03-31	Androstane 17-carboxylic acid esters,their preparation and pharmaceutical compositions containing them
ATE111353T1 (de)	1994-09-15	Makrolide zur behandlung reversibler obstruktiver atemwegserkrankungen.
ZA899670B (en)	1990-11-28	Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
AP9300589A0 (en)	1994-01-31	Novel 17a and 17b substituted acyl-3-carboxy 3,5-diene steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-a-reductase.
OA06613A (fr)	1981-08-31	Nouveaux dérivés d'amino-14 stéroïdes et procédé pour leur préparation.
KR940701260A (ko)	1994-05-28	스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법
HU9301814D0 (en)	1993-09-28	D-homo-(16-en)-11beta-aryl-4-oestrenes as well as methods for producing and applying them as medicament
ES8707518A1 (es)	1987-08-01	Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol
DE60031557D1 (de)	2006-12-07	Steroide, ihre herstellung , pharmazeutische zusammensetzungen mit ihnen und verwendungen dieser verbindungen
TW343976B (en)	1998-11-01	17-substituted steroids useful in cancer treatment
WO1990015067A3 (fr)	1991-01-24	NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES
GB961101A (en)	1964-06-17	Steroid compounds

Legal Events

Date	Code	Title	Description
1998-04-05	FF	Patent granted
1998-12-06	KB	Patent renewed
1999-08-17	KB	Patent renewed
2003-06-24	KB	Patent renewed
2011-03-31	KB	Patent renewed
2012-07-31	EXTF	Application for patent extension filed
2013-03-24	EXTG	Extension of patent term granted	Extension date: 20130916
2013-11-28	PEL	Intention of commissioner to extend period of protection
2014-09-30	EXTN	Extension order renewed